FTC settlements
This article was originally published in The Tan Sheet
Executive Summary
Federal Trade Commission consent agreements with the Arthritis Pain Care Center and Body Systems Technology are made final by 4-0 votes, the commission announces Sept. 20. Under the terms of the deals, the Arthritis Pain Care Center is not allowed to make cancer treating claims for its fatty acid product, while Body Systems Technology may not claim its shark's cartilage and cat's claw products are effective treatments for cancer, HIV/AIDS or arthritis. FTC announced the proposed agreements June 24 (1"The Tan Sheet" June 28, p. 4)
You may also be interested in...
FTC Highlights Dietary Supplements In Anti-Fraud Consumer Guide
A Federal Trade Commission consumer guide on fraudulent marketing on the Internet includes a special section on dietary supplements.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands